Skip to main content
. 2017 Aug 28;4(2):233–246. doi: 10.1007/s40744-017-0076-0

Table 4.

Percentage of patients at week 24 achieving complete resolution of enthesitis and dactylitis in the FUTURE-1 and FUTURE-2 trials using non-responder imputation.

Mease et al. [5]

Enthesitis Dactylitis
Secukinumab 300 mg (%) Secukinumab 150 mg (%) Secukinumab 75 mg (%) Placebo (%) Secukinumab 300 mg (%) Secukinumab 150 mg (%) Secukinumab 75 mg (%) Placebo (%)
FUTURE-1 46.0 48.8 12.8 48.8 56.7 15.5
FUTURE-2 48.2 42.2 32.4 21.5 56.5 50 30.3 14.8